You can buy or sell ABEO and other stocks, options, ETFs, and crypto commission-free!
Abeona Therapeutics Inc. Common Stock, also called Abeona Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. Read More It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Seeking AlphaMar 19
Abeona Therapeutics Inc. (ABEO) CEO João Siffert on Q4 2018 Results - Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2018 Results Earnings Conference Call March 19, 2019 10:00 AM ET Company Participants Sofia Warner - Director of IR João Siffert - CEO, Head of Research & Development and Chief Medical Officer Timothy Miller - President, Chief Scientific Officer Christine Berni-Silverstein - CFO Conference Call Participants Kennen MacKay - RBC Capital Markets Elemer Piros - Cantor Fitzgerald Maury Raycroft - Jefferies Fang-Ke Huang - SunTrust Liav Abraham - Citi Operator...
Houston ChronicleMar 18
Abeona Therapeutics: 4Q Earnings Snapshot
DALLAS (AP) _ Abeona Therapeutics Inc. (ABEO) on Monday reported a loss of $17.5 million in its fourth quarter. On a per-share basis, the Dallas-based company said it had a loss of 36 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share. The drug developer posted revenue of $500,000 in the period, falling short of Street forecasts. Three analysts surveyed by Zacks expected $1.7 million. Fo...
Stock Price, News, & Analysis for Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene ther...
-$0.40 per share
-$0.36 per share